Skip to content

Study · Randomized controlled trial · 2025

7 results

Time spent in glycaemic control with sustained body weight reduction with tirzepatide: A post hoc analysis of the SURPASS clinical trial programme.

Bergman BK, Rosenstock J, Garvey WT, Batterham RL, Chen Y, Liu M, Sharma P, Karanikas CA, Thieu VT

Diabetes, obesity & metabolism13 Mar 2025Cited by 3 (Europe PMC)

PMID40083081 (opens in a new tab)PMCIDPMC12046485 (opens in a new tab)DOI10.1111/dom.16337 (opens in a new tab)PepBankPUB-40083081
Read at sourcePubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, tirzepatide gave a longer median time with HbA1c below 7.0% than semaglutide 1 mg in 40-week studies.

    In plain wordsIn adults with type 2 diabetes, people on tirzepatide spent more time with HbA1c below 7.0% than people on semaglutide 1 mg.

    Peptide
    Tirzepatide
    Outcome
    IncreaseTime with HbA1c below 7.0%, 40-week studies
    Study

    n: not reported in source

    Comparator
    Semaglutide 1 mg
    Analysis
    Exploratory
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    5, 10 or 15 mg once weekly · 40 weeksAs given in this study (human).

    Measurements

    Median time with HbA1c <7.0%
    80%
    tirzepatide
    Median time with HbA1c <7.0%
    70%
    semaglutide

    Source sentences

    Summary
    Median time spent with HbA1c < 7.0% (53 mmol/mol) was 80% (tirzepatide) versus 70% (semaglutide)
    1 context sentence
    Summary · context
    Participants (N = 6246) from SURPASS 1-5 were randomized to once weekly tirzepatide (5, 10 or 15 mg) or comparator (once weekly placebo, once weekly semaglutide 1 mg, insulin degludec or insulin glargine).
  2. 02HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, tirzepatide gave a longer median time with HbA1c below 7.0% than placebo in 40-week studies.

    In plain wordsIn adults with type 2 diabetes, people on tirzepatide spent more time with HbA1c below 7.0% than people on placebo.

    Peptide
    Tirzepatide
    Outcome
    IncreaseTime with HbA1c below 7.0%, 40-week studies
    Study

    n: not reported in source

    Comparator
    Placebo
    Analysis
    Exploratory
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    5, 10 or 15 mg once weekly · 40 weeksAs given in this study (human).

    Measurements

    Median time with HbA1c <7.0%
    80%
    tirzepatide
    Median time with HbA1c <7.0%
    0%
    placebo

    Source sentences

    Summary
    Median time spent with HbA1c < 7.0% (53 mmol/mol) was 80% (tirzepatide) versus 70% (semaglutide) and 0% (placebo)
    1 context sentence
    Summary · context
    Participants (N = 6246) from SURPASS 1-5 were randomized to once weekly tirzepatide (5, 10 or 15 mg) or comparator (once weekly placebo, once weekly semaglutide 1 mg, insulin degludec or insulin glargine).
  3. 03HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, tirzepatide gave a longer median time with HbA1c below 7.0% than insulin degludec in 52-week studies.

    In plain wordsIn adults with type 2 diabetes, people on tirzepatide spent more time with HbA1c below 7.0% than people on insulin degludec.

    Peptide
    Tirzepatide
    Outcome
    IncreaseTime with HbA1c below 7.0%, 52-week studies
    Study

    n: not reported in source

    Comparator
    Insulin degludec
    Analysis
    Exploratory
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    5, 10 or 15 mg once weekly · 52 weeksAs given in this study (human).

    Measurements

    Median time with HbA1c <7.0%
    77 to 85%
    tirzepatide
    Median time with HbA1c <7.0%
    62%
    insulin degludec

    Source sentences

    Summary
    77%-85% (tirzepatide) versus 62% (insulin degludec)
    1 context sentence
    Summary · context
    Participants (N = 6246) from SURPASS 1-5 were randomized to once weekly tirzepatide (5, 10 or 15 mg) or comparator (once weekly placebo, once weekly semaglutide 1 mg, insulin degludec or insulin glargine).
  4. 04HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, tirzepatide gave a longer median time with HbA1c below 7.0% than insulin glargine in 52-week studies.

    In plain wordsIn adults with type 2 diabetes, people on tirzepatide spent more time with HbA1c below 7.0% than people on insulin glargine.

    Peptide
    Tirzepatide
    Outcome
    IncreaseTime with HbA1c below 7.0%, 52-week studies
    Study

    n: not reported in source

    Comparator
    Insulin glargine
    Analysis
    Exploratory
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    5, 10 or 15 mg once weekly · 52 weeksAs given in this study (human).

    Measurements

    Median time with HbA1c <7.0%
    77 to 85%
    tirzepatide
    Median time with HbA1c <7.0%
    23%
    insulin glargine

    Source sentences

    Summary
    77%-85% (tirzepatide) versus 62% (insulin degludec) and 23% (insulin glargine)
    1 context sentence
    Summary · context
    Participants (N = 6246) from SURPASS 1-5 were randomized to once weekly tirzepatide (5, 10 or 15 mg) or comparator (once weekly placebo, once weekly semaglutide 1 mg, insulin degludec or insulin glargine).
  5. 05HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, time spent with HbA1c below 7.0% was generally similar across all tirzepatide doses in each study.

    In plain wordsIn adults with type 2 diabetes, the time with HbA1c below 7.0% was about the same for all tirzepatide doses.

    Peptide
    Tirzepatide
    Outcome
    No significant changeTime with HbA1c below 7.0% across tirzepatide doses
    Study

    n: not reported in source

    Comparator
    Other tirzepatide doses
    Analysis
    Exploratory
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    5, 10 or 15 mg once weeklyAs given in this study (human).

    Source sentences

    Summary
    Time spent with HbA1c < 7.0% (53 mmol/mol) was generally similar across all tirzepatide doses in each study.
    1 context sentence
    Summary · context
    Participants (N = 6246) from SURPASS 1-5 were randomized to once weekly tirzepatide (5, 10 or 15 mg) or comparator (once weekly placebo, once weekly semaglutide 1 mg, insulin degludec or insulin glargine).
  6. 06HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, tirzepatide gave dose-dependent increases in time with at least 5% body weight reduction (median 20%-77% across doses versus 25% with semaglutide 1 mg).

    In plain wordsIn adults with type 2 diabetes, time with 5% weight loss rose with tirzepatide dose (20% to 77%) versus 25% with semaglutide 1 mg.

    Peptide
    Tirzepatide
    Outcome
    MixedTime with at least 5% body weight reduction
    Study

    n: not reported in source

    Comparator
    Semaglutide 1 mg
    Analysis
    Exploratory
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    5, 10 or 15 mg once weeklyAs given in this study (human).

    Measurements

    Median time with at least 5% weight reduction
    20 to 77%
    tirzepatide
    Median time with at least 5% weight reduction
    25%
    semaglutide 1 mg

    Source sentences

    Summary
    Dose-dependent increases in time spent with ≥5% body weight reduction were observed with tirzepatide (median time spent: 20%-77% with tirzepatide versus 25% with semaglutide 1 mg) (p < 0.001).
    1 context sentence
    Summary · context
    Participants (N = 6246) from SURPASS 1-5 were randomized to once weekly tirzepatide (5, 10 or 15 mg) or comparator (once weekly placebo, once weekly semaglutide 1 mg, insulin degludec or insulin glargine).
  7. 07HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, tirzepatide gave a longer time with HbA1c at or below 6.5% and at least 5% weight reduction than semaglutide.

    In plain wordsIn adults with type 2 diabetes, people on tirzepatide spent more time with both lower HbA1c and 5% weight loss than people on semaglutide.

    Peptide
    Tirzepatide
    Outcome
    IncreaseTime with HbA1c at or below 6.5% and at least 5% body weight reduction
    Study

    n: not reported in source

    Comparator
    Semaglutide 1 mg
    Analysis
    Exploratory
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    5, 10 or 15 mg once weeklyAs given in this study (human).

    Measurements

    Median time with HbA1c =5% weight reduction
    35 to 60%
    tirzepatide
    Median time with HbA1c =5% weight reduction
    7%
    semaglutide

    Source sentences

    Summary
    Tirzepatide-treated participants experienced longer time spent with HbA1c ≤ 6.5% (48 mmol/mol) and ≥5% body weight reduction versus semaglutide (median: 35%-60% vs. 7%) (p < 0.001).
    1 context sentence
    Summary · context
    Participants (N = 6246) from SURPASS 1-5 were randomized to once weekly tirzepatide (5, 10 or 15 mg) or comparator (once weekly placebo, once weekly semaglutide 1 mg, insulin degludec or insulin glargine).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:07 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.